Navigation Links
NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
Date:4/15/2009

SAN DIEGO, April 15 /PRNewswire/ -- NexBio, Inc. announced today that it has completed the formation of a new Clinical Advisory Board (CAB) to complement its existing group of Senior Advisers. NexBio recently completed a First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational drug candidate for influenza. The new CAB will guide NexBio throughout the clinical development of this novel medicine, helping the company to conduct advanced product development to address the threat of a potential influenza pandemic. The CAB is chaired by Andrew Pavia, M.D., who is joined by Robert Belshe, M.D., Kathryn Edwards, M.D., Allison McGeer, M.D., FRCPC, and Richard Whitley, M.D.

"These individuals are among the most highly regarded thought leaders in the field of clinical development of drugs for respiratory viral infections," said Ron Moss, M.D., NexBio's Executive Vice President, Clinical Development & Medical Affairs. "We expect that their depth of knowledge and experience will contribute enormously to the goal of developing Fludase for the prevention and treatment of Influenza-Like Illness caused by influenza, parainfluenza, and potential pandemic strains such as H5N1. With the development of drug resistance to currently licensed antivirals, our distinguished CAB recognizes the importance of determining the clinical utility of DAS181 against emerging strains of influenza."

Dr. Pavia is the George and Esther Gross Presidential Professor and Chief of the Division of Pediatric Infectious Diseases at the University of Utah Health Sciences Center. He is very active as an infectious disease investigator and in policy. Dr. Pavia serves on several advisory committees for federal and state government on vaccine policy, biodefense, and pandemic influenza preparedness. He leads several committees of the Infectious Diseases Society of America and has been a member of the Institute of Medicine C
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NexBio to Present at 2009 Biotech Showcase
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
4. Gen-Probe Completes Acquisition of Tepnel Life Sciences
5. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
6. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
7. Atritech Completes $30 Million Financing
8. Roche Completes Tender Offer for Genentech
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
11. Sangart, Inc. Completes Series F Funding Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual ... 2014, from 12:00 to 1:00 p.m. EDT. The session ... and practice-oriented instruction, designed for working professionals. Participants will ... their career in the biotechnology industry. , If interested ... About UMBC’s Biotechnology Graduate Programs, UMBC offers a variety ...
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty year history ... successful broadcast of a live surgery by St. Luke’s ... FAMBS, and Maher El Chaar, MD, FACS, FAMBS, using ... This sleeve gastrectomy surgery was performed and broadcast live ... surgeons from around the world during the 5th International ...
(Date:9/12/2014)... Advancing the front lines of ... and biological threats is the mission of an ... (WPI) and the Georgian National Academy of Sciences, ... and Security Programme of the North Atlantic Treaty ... Workshop series, the event is titled “Nanotechnology to ...
(Date:9/12/2014)... On Thursday, September 11, 2014, the ... Industrial Average finished the day 0.12% lower at 17,049.00, and ... were broad based as seven out of ten sectors ended ... Index ended the day at 741.83, down 0.33%, while the ... has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... WILL BE FOR USE IN POINT-OF-CARE BONE MARROW PROCESSING, ... KOOL ), a leading supplier of innovative products ... said it has,received authorization from the FDA to begin ... laboratory setting or intraoperatively,for preparation of a cell concentrate ...
... water through point-of-use ... ultrafiltration, NEW ... device company, announced today that it will be exhibiting its,Dual Stage ... Technical Exhibition in National Harbor,Maryland, July 20th-23rd, 2008. Building on the ...
... July 14 Phlo Corporation,(Pink Sheets: PHCP) (the ... California of its vitality beverage, AQISS(TM),will be significantly ... of,the largest specialty beverage distributors in the San ... reached an agreement in principal with Morris,Distributing providing ...
Cached Biology Technology:ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 2ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 3ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 4Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Phlo Affiliate Announces Significant Distribution Expansion In California 2
(Date:9/15/2014)... in the Department of Science and Technology in Society ... at Virginia Tech, has won a 2014 National Science ... prospects and problems of creating a global nuclear emergency ... I Nuclear Power Plant in March 2011 was a ... emergencies, Schmid said. Three of the plant,s six nuclear ...
(Date:9/15/2014)... the oceans, there must be enough dissolved oxygen ... oxygen-starvation produces "dead zones" that decimate marine fisheries ... levels decline, energy is increasingly diverted away from ... impacts on the ecology and biogeochemistry of the ... minimum zones (OMZs) have expanded due to climate ...
(Date:9/15/2014)... and cognitive function may play roles in one,s musical ... pitch, timbre, tone durations, and formal structure in music. ... explain that extremes in musical aptitude (extreme capacity/no capacity) ... individuals having moderate aptitude. , "This is a typical ... genes, and it is influenced to varying degrees by ...
Breaking Biology News(10 mins):'Nuclear disasters don't respect national boundaries' 2Decoding virus-host interactions in the oxygen-starved ocean 2Decoding virus-host interactions in the oxygen-starved ocean 3Decoding virus-host interactions in the oxygen-starved ocean 4Decoding virus-host interactions in the oxygen-starved ocean 5
... Established in 2007 and based in Toronto, ArcticDx has ... kind and specifically designed to determine one,s inherited risk ... of acquired blindness in the developed world, affecting over ... investment to undertake studies in support of a planned ...
... One of the many advantages of maintaining a normal body ... healthy heart. Fat tissue is increasingly seen as more than ... organ that normally produces high levels of a cardioprotective hormone ... has long been a mystery, and now a team led ...
... the Morrison Natural History Museum have again discovered infant ... near the town of Morrison. Dating from the Late ... made before the Rocky Mountains rose, when Morrison was ... tracks represent infant sauropods, according to discoverer Matthew Mossbrucker, ...
Cached Biology News:OGI invests in personalized medicine for age-related macular degeneration 2Study finds fat hormone's long-sought link to heart protection 2Morrison Natural History Museum discovers baby sauropod tracks 2Morrison Natural History Museum discovers baby sauropod tracks 3
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent - EDTA, 10 L...
... gel electrophoresis into an automated, high-throughput operation ... pre-cast system is ideal for analyzing multiple ... more. Fully automated, robot-compatible, and ready to ... makes your high-throughput screening assignments as easy ...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: